Scientific deep-dive

Can You Lower the Dose and Keep the Weight Off?

Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Once the weight is off, what is the smallest amount of drug that holds it? A 2026 randomized trial finally tested that, comparing people who stayed on their maximum tolerated tirzepatide dose against people dropped to 5 mg and people moved to placebo. The weight numbers are the ones that will get quoted. The number that matters more is how many in each group needed rescue therapy: 8%, 25% and 67%.[1]

What was compared

Participants who had already lost weight on tirzepatide were randomized to continue at their maximum tolerated dose, to step down to 5 mg, or to switch to placebo, and followed to week 112. They began with a mean body weight of 113.8 kg and a mean BMI of 40.1.[1]

Percent change in body weight from baseline to week 112, and the proportion who needed rescue therapy. All comparisons against placebo p<0.0001.
GroupWeight changeNeeded rescue therapy
Maximum tolerated dose−21.9%11 of 138 (8%)
Stepped down to 5 mg−16.6%35 of 142 (25%)
Placebo−9.9%60 of 90 (67%)

So a lower dose does hold a substantial part of the loss, but meaningfully less than staying put does. The authors say reducing to 5 mg might provide a valuable alternative to discontinuation, which is a careful phrase and the right one: better than stopping, worse than continuing.[1]

The column nobody will quote

From week 84, anyone who had regained more than half of the weight they lost could be put back on tirzepatide as rescue therapy. That turns a group average into a count of people who slipped back that far.

Two thirds of the placebo group needed rescue therapy, against 8% of those who stayed on the full dose.

It also reframes the dose-reduction question. Stepping down to 5 mg tripled the rescue rate against staying at the full dose (25% against 8%), while still being far better than the 67% on placebo. If you are weighing a lower dose to save money or reduce side effects, that tripling is the cost, and the group averages do not show it. How the doses compare on the way down is in which Zepbound dose works best.

What this means for microdosing

We wrote recently that no randomized trial of microdosing exists, and that remains true: 5 mg of tirzepatide is a labeled dose, not a microdose, and this trial does not test the sub-labeled dosing that 62 sellers in our register offered when we counted in August 2026. The sellers pricing a tirzepatide microdose plan today are on a board of their own.

But it is the closest randomized evidence to the underlying idea, and it points both ways at once. Less drug did hold much of the loss, which is the strongest support the microdosing premise has ever had. And less drug did measurably worse on how many people regained more than half their loss, which is the part the marketing will leave out.

Note what the placebo group did not do. They were still 9.9% below baseline at week 112, not back where they started. The popular version of this story, that stopping means regaining everything, is stronger than the evidence. Our article on stopping covers the fuller picture.

How to use this

  • Long-term treatment is the design assumption now. The trial’s own framing is that ongoing therapy is often necessary to maintain the reduction. That makes affordability a clinical question as well as a financial one.
  • A dose reduction is a legitimate clinical option, and it is one to make with a prescriber who can watch what happens rather than by choosing a cheaper subscription tier. If stopping outright is on the table, see what happens when you stop tirzepatide.
  • Response varies. The authors say so explicitly; group means do not tell you which group you are in.
  • Side effects were mostly during escalation, and mostly mild to moderate gastrointestinal, which matters if tolerability is what is driving you toward a lower dose.

If money is part of the reason for stepping down, check how your seller prices doses before assuming a lower one is cheaper. Among sellers of compounded tirzepatide, which is not an approved product, CoreAge Rx, 50 Stars Health and Novi charge one monthly price at every dose. So do Yucca Health and Oxford’s Medical Weight Loss (The Calibrate Clinic), which now serves Louisiana patients only. At any of them a lower dose saves nothing, and a higher one costs no more.

MyStart Health prices the same way: a price-lock guarantee keeps its all-inclusive monthly rate flat as the dose changes. Its public pages now mention compounded tirzepatide only in an injection guide, so confirm it is still offered before planning around it.

The arithmetic runs the other way where the price follows the dose. Citizen Meds and VitaStir sell monthly kits that cost more at each step up, and Arc-1 sells each dose separately at a price that climbs with the strength. There, a step-down does lower the bill, which is the trade the rescue-therapy column asks you to weigh with your prescriber.

Frequently Asked Questions

Partly. In SURMOUNT-MAINTAIN, people stepped down to 5 mg were 16.6% below baseline at week 112 against 21.9% for those staying at their maximum tolerated dose and 9.9% for placebo. The authors say reducing to 5 mg might provide a valuable alternative to discontinuation. In short, it is better than stopping and worse than continuing.
Rescue therapy. 25% of the 5 mg group needed it against 8% of those who stayed at the full dose, roughly triple. Rescue was given to people who had regained more than half of the weight they lost, so it counts how many slipped back that far, which the average weight change does not show.
No. 5 mg is a labeled tirzepatide dose, not a microdose, so this does not test the sub-labeled dosing sold by many telehealth sellers. It is the closest randomized evidence to the idea, and it supports the premise while showing the lower dose does measurably worse.
Not in this trial. The placebo group was still 9.9% below baseline at week 112 and had kept a substantial part of the loss. But two thirds of them regained enough (more than half of their loss) to receive rescue therapy, so the average hides how many people slipped back substantially.
That is the direction the evidence points, and the trial's own conclusion is that long-term treatment is often necessary to maintain the reduction and its cardiometabolic benefits. It makes whether you can keep affording the drug part of the clinical decision rather than separate from it.

References

  1. 1.Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised trial The Lancet. 2026. PMID: 42119587.

Stretching Doses to Save Money

At list prices above a thousand dollars a month, people stretch these drugs. Two papers argue fortnightly dosing keeps most of the weight loss, on a mathematical model and a case series of two patients.

8 min read

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

What People Actually Do After Stopping

Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.

5 min read

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

6 min read

The Cardiovascular Cost of Stopping

A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

5 min read

Stopping as a Clinical Transition

A review argues discontinuation is a high-risk clinical transition, and reports an association with later heart disease that another review says barely exists as data. Both are describing the same thin literature.

6 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $69/mo + membership

Get started →
Read full review →
6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →